The utility of PU.1 as an immunohistochemical marker for histiocytic and dendritic lesions of the skin

American Journal of Dermatopathology

Volumn 31, Issue 5, 2009, Pages 432-435

  Muirhead, Desirae ^a   Stone, Mary Seabury ^a   Syrbu, Sergei I ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; TRANSCRIPTION FACTOR PU 1; ONCOPROTEIN; PROTO ONCOGENE PROTEIN SPI 1; PROTO-ONCOGENE PROTEIN SPI-1; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DENDRITIC CELL; DERMATOFIBROMA; FIBROSIS; HISTIOCYTIC SKIN DISEASE; HISTIOCYTOMA; HISTIOCYTOSIS X; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; JUVENILE XANTHOGRANULOMA; MAJOR CLINICAL STUDY; MELANOMA; PAPULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETICULOHISTIOCYTOSIS; SKIN DISEASE; SKIN TUMOR; STAINING; HISTIOCYTE; LANGERHANS CELL; METABOLISM; PATHOLOGY;

HISTIOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LANGERHANS CELLS; PROTO-ONCOGENE PROTEINS; SKIN NEOPLASMS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 69849109311     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31818866a7     Document Type: Article

References (12)

1. Dekoter R, Singh H. Regulation of B-lymphocyte and macrophage development by graded expression of PU.1. Science. 2000;288: 1439-1441.
2. Oikawa T, Yamada T, Kihara-Negishi F, et al. The role of the Ets family transcription factor PU.1 in hematopoietic cell differentiation, proliferation and apoptosis. Cell Death Differ. 1999;6:599-608.
3. Nemeth AJ, Penneys NS, Bernstein HV. Fibrous papule: A tumor of fibrohistiocytic cells that contain factor XIIIa. J Am Acad Dermatol. 1998; 19:1102-1106.
4. Nemeth AJ, Penneys NS. Factor XIIIa is expressed by fibroblasts in fibrovascular tumors. J Cutan Pathol. 1989;16:226-271.
5. Lautier R, Wolff HH, Jones RE. An immunocytochemical study or dermatofibrosarcoma protuberans supports its fibroblastic character and contradicts neuroectodermal or histiocytic component. Am J Dermato-pathol. 1990;12:25-30.
6. Dowd JO, Laidler P. Progression of dermatofibrosarcoma protuberans to malignant fibrous histiocytoma: A report of a case with implications of tumor histiogenesis. Hum Pathol. 1988;19:368-370.
7. Ma CK, Zarbo RJ, Gown AM. Immunocytochemical characterization of atypical fibroxanthoma and dermatofibrosarcoma protuberans. Am J Clin Pathol. 1991;97:478-483.
8. Hashimoto K, Brownstein MH, Jakobec FA. Dermatofibrosarcoma protuberans: A tumor with perineural and endoneurial cell features. Arch Dermatol. 1974;110:874-875.
9. Cerio R, Spaull J, Jones EW. Histiocytoma cutis: A tumor of dermal dendrocytes (dermal dendrocytoma). Br J Dermatol. 1989;120:197-206.
10. Frierson HF, Cooper PH. Myxoid variant of dermatofibrosarcoma protuberans. Am J Surg Pathol. 1983;7:445-450.
11. Dupree WB, Langloss JM, Weiss SW. Pigmented dermatofibrosarcoma protuberans (Bednar tumor): A pathologic, ultrastructural and immuno-cytochemical study. Am J Surg Pathol. 1985;9:630-639.
12. DeWit NJW, Van Muijen GNP, Ruiter DJ. Immunohistochemistry in melanocytic proliferative lesions. Histopathology. 2004;44:517-541.